Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 27, 2026

Broader Market Rallies on Tech Strength and Solid Earnings

View original at nasdaq.com
Broader Market Rallies on Tech Strength and Solid Earnings The S&P 500 Index ($SPX) (SPY) today is up +0.47%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.84%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.87%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Deutsche Bank upgraded CoreWeave to buy from hold with price target of $140

    80% confidence

  • General Motors forecast full-year adjusted EPS of $11.00 to $13.00

    80% confidence

  • Sanmina forecast Q2 revenue of $3.1 billion to $3.4 billion

    80% confidence

  • Roper Technologies forecast 2026 adjusted EPS continuing operations of $21.30 to $21.55

    80% confidence

  • Micron Technology plans to invest $24 billion in Singapore and expand memory-chip capacity

    80% confidence

  • UnitedHealth Group forecast a decline in 2026 revenue, the first annual contraction in more than 30 years

    80% confidence

  • President Trump threatened 100% tariffs on US imports from Canada

    80% confidence

  • Senate Democrats threatened to block government funding deal over Department of Homeland Security/ICE funding

    80% confidence

  • S&P 500 earnings growth expected to climb by 8.4% in Q4

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com